HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma

Experimental and Molecular Pathology

Volumn 66, Issue 2, 1999, Pages 163-169

  Afify, Alaa M ^a   Werness, Bruce A ^b   Mark, Hon Fong L ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Fluorescent in situ hybridization; HER 2 neu oncogene amplification; Ovarian cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; ONCOGENE NEU; OVARY CARCINOMA; PROGNOSIS;

EID: 0032766144     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.1999.2255     Document Type: Article

References (41)

1. Afify A., Bland K. I., Mark H. F. L. Fluorescent in situ hybridization assessment of chromosome 8 copy number in breast cancer. Breast Cancer Res. Treatment. 38:1996;201-208.
2. Afify A., Mark H. F. L. FISH assessment of chromosome 8 copy number in stage I and stage II infiltrating ductal carcinoma of the breast. Cancer Genet. Cytogenet. 97:1997;101-105.
3. Afify A., Mark H. F. L. Trisomy 8 in rhabdomyosarcoma detected by FISH. Cancer Genet. Cytogenet. 108:1999;127-132.
4. Bargmann C. L., Hung M. C., Weinberg R. A. The neu oncogene encodes an apidermal growth factor receptor-related protein. Nature (Lond). 319:1986;226-229.
5. Berchuck A., Kamel A., Whitaker R., Kerns B. Over expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
6. Gynecol. Oncol. 25:1986;383.
7. Hetzel D. J., Wilson T. O., Keeney G. L. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol. Oncol. 47:1992;179-185.
8. Hopman A. H. N., Van Hoorenm E., Van de Kaa, Vooijs C. A., Ramaekers F. C. S. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancer. Mod. Pathol. 4:1991;503-513.
9. Kallioniemi O. P., Kallioniemi A., Kurisu W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA. 89:1992;5321-5325.
10. Kim S. Y., Lee J. S., Ro J. Y., Gay M. L., Hong W. K., Hittleman W. N. Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization: Mapping/genotype heterogeneity. Am. J. Pathol. 142:1993;307-317.
11. Kokai Y., Cohen J. A., Drebin J. A., Greene M. I. Stage and tissue specific expression of the neu oncogene in rat development. Proc. Natl. Acad. Sci. USA. 84:1987;8498-8501.
12. Mark H. F. L. Fluorescent in situ hybridization as an adjunct to conventional cytogenetics. Ann. Clin. Lab. Sci. 24:1994;153-163.
13. Mark H. F. L., Afify A., Taylor W., Santoro K., Lathrop J. C. A subset of gestational trophoblastic disease (GTD) characterized by abnormal chromosome 8 copy number detected by FISH? Cancer Genet. Cytogenet. 96:1997a;1-6.
14. Mark H. F. L., Aswad B., Bassily N., Taylor W., Brown S., Sun C.-L., Samy M., Zolnierz K., Wong E., Kim D., Bland K. I., Hsu P. H. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. Genet. Med. 1:1999;98-103.
15. Mark H. F. L., Brown S., Samy M., Sun C.-L., Santoro K., Afify A. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology. 66:1998;59-63.
16. Mark H. F. L., Huth A., Santoro K., Ferreira K., and Barker B. Sequential flow cytometry and FISH for the study of formalin-fixed paraffin-embedded breast cancer tissues. Cancer Genet. Cytogenet. 98:1997b;1-5.
17. Mark H. F. L., Mills D., Kim E., Santoro K., Quddus M., Lathrop J. C. Fluorescent in situ hybridization assessment of chromosome copy number in buccal mucosal cells. Cytobios. 87:1996;117-126.
18. Mark H. F. L., Mills D., Santoro K., Quddus M., Lathrop J. C. Fluorescent in situ hybridization (FISH) analysis of cervical smears: A pilot study of 20 cases. Ann. Clin. Lab. Sci. 27:1997c;224-229.
19. Mark H. F. L., Rehan J., Mark S., Santoro K., Zolnierz K. FISH analysis of single-cell trisomies for determination of clonality. Cancer Genet. Cytogenet. 100:1997d;1-5.
20. Mark H. F. L., Taylor W., Afify A., Riera D., Rausch M., Huth A., Gray Y., Santoro K., Bland K. I. Stage I and stage II infiltrating ductal carcinoma of the breast analyzed for chromosome 8 copy number using FISH. Pathobiology. 65:1997e;184-189.
21. Mark H. F. L., Grollino M. G., Sulaiman R. A., Lathrop J. C. Fluorescent in situ hybridization (FISH) assessment of chromosome copy number in gestational trophoblastic disease. Ann. Clin. Lab. Sci. 25:1995;291-296.
22. Masuda H., Battifora H., Yokota J., Meltzer S., Cline M. J. Specificity of proto-oncogene amplification in human malignant diseases. Mol. Biol. Med. 4:1987;213-227.
23. Miranda R. N., Mark H. F. L., Medeiros L. J. Fluorescent in situ hybridization in routinely processed bone marrow aspirate clot and core biopsy sections. Am. J. Pathol. 145:1994;1-6.
24. Pinkel D., Strawne R., Gray J. Cytogenetic analysis using quantitative high sensitivity, fluorescence hybridization. Proc. Natl. Acad. Sci. USA. 83:1986;2934-2938.
25. Popescu N. C., King C. R., Kraus M. H. Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to band q12-21.32. Genomics. 4:1989;362-366.
26. Sauter G., Moch H., Moor D., Carroll P. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:1993;2199-2203.
27. Schechter A. L., Stern D. F., Vaidyananthan L. The neu oncogene: An erb-B-related gene encoding a 185,000-M tumour antigen. Nature (Lond). 312:1984;513-516.
28. Serov S. F., Scully R. E., Sobin L. H. International histologic classifications of tumors, No. 9. Histologic typing of ovarian tumors. 1973;World Health Organization, Geneva.
29. Slamon D. J., Clark G. H., Wong S. G., Levin W. J. Human breast cancer: Correlation of relapse and survival with amplification of the Her2-/neu oncogene. Science. 235:1987;177-182.
30. Slamon D. J., Godolphin W., Jones L. A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
31. Stenman G., Sandros J., Nordkvist A. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer. 3:1991;128-135.
32. Teneriello M. G., and Park R. C. Early detection of ovarian cancer. Cancer. 45:1995;71-87.
33. Tyson F. L., Boyer C. M., Kaufman R., Fowlers W. C., O'Briant K., Cram G., Crews J. R., Soper J. T., Daly L., Haskill J. S. Overexpression and amplification of the c-erbB-2 (HER-2/neu) proto-oncogene in epithelial ovarian tumors and cell lines. Am. J. Obstet. Gynecol. 165:1991;640-646.
34. Wingo P. A., Tong T., Bolden S. Cancer statistics 1995. Cancer. 45:1995;8-30.
35. Wong Y. F. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol. Obstet. Invest. 40:1995;209-212.
36. Wright C., Angus B., Nicholson S. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 49:1989;2087-2090.
37. Yamamoto N., Ikawa S., Akiyama T. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 319:1986;230-234.
38. Yonemura Y., Ninomiya I., Ohoyama S. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 67:1991;2914-2918.
39. Young S. R., Liu W.-H., Brock J.-A., Smith S. T. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer. 16:1996;130-137.
40. Zhang X., Silva E., Gershenson D., Hung M.-C. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. Oncogene. 4:1989;985-989.
41. Zhou D., Battifora H., Yokota J., Yamamoto T., Cline M. J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res. 47:1987;6123-6125.